Clearpoint Neuro Stock Performance
| CLPT Stock | USD 13.67 0.29 2.17% |
The firm shows a Beta (market volatility) of 2.12, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Clearpoint Neuro will likely underperform. At this point, Clearpoint Neuro has a negative expected return of -0.0449%. Please make sure to confirm Clearpoint Neuro's skewness, and the relationship between the total risk alpha and day median price , to decide if Clearpoint Neuro performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Clearpoint Neuro has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Clearpoint Neuro is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (2.12) | Five Day Return 4.53 | Year To Date Return (13.90) | Ten Year Return (62.42) | All Time Return (55.40) |
Last Split Factor 1:40 | Dividend Date 2016-07-27 | Last Split Date 2016-07-27 |
1 | Acquisition by Dalessandro Danilo of 1949 shares of Clearpoint Neuro at 4.53 subject to Rule 16b-3 | 12/31/2024 |
2 | Acquisition by Mazin Sabra of 65252 shares of Clearpoint Neuro subject to Rule 16b-3 | 01/10/2025 |
3 | Acquisition by Mazin Sabra of 6913 shares of Clearpoint Neuro subject to Rule 16b-3 | 01/17/2025 |
4 | ClearPoint Neuro Surges 22.5 percent Is This an Indication of Further Gains | 01/22/2025 |
5 | Disposition of 908 shares by Stigall L. Jeremy of Clearpoint Neuro at 16.72 subject to Rule 16b-3 | 02/21/2025 |
6 | ClearPoint Neuro Q4 2024 Earnings Preview | 02/25/2025 |
7 | ClearPoint Neuro reports Q4 results | 02/26/2025 |
8 | ClearPoint Neuro Inc Q4 2024 Earnings Call Highlights Strong Revenue Growth and ... | 02/27/2025 |
9 | ClearPoint Neuro Full Year 2024 Earnings Misses Expectations | 02/28/2025 |
10 | Acquisition by Joseph Burnett of 132841 shares of Clearpoint Neuro subject to Rule 16b-3 | 03/03/2025 |
11 | Disposition of 47407 shares by Joseph Burnett of Clearpoint Neuro subject to Rule 16b-3 | 03/06/2025 |
12 | Acquisition by Dalessandro Danilo of 18765 shares of Clearpoint Neuro subject to Rule 16b-3 | 03/10/2025 |
13 | Disposition of 4146 shares by Dalessandro Danilo of Clearpoint Neuro subject to Rule 16b-3 | 03/11/2025 |
14 | Disposition of 42414 shares by Joseph Burnett of Clearpoint Neuro subject to Rule 16b-3 | 03/12/2025 |
15 | Disposition of 2106 shares by Dalessandro Danilo of Clearpoint Neuro at 12.7 subject to Rule 16b-3 | 03/13/2025 |
16 | Disposition of 13050 shares by Mazin Sabra of Clearpoint Neuro subject to Rule 16b-3 | 03/14/2025 |
17 | Micro Medical Solutions Appoints Board of Directors | 03/20/2025 |
| Begin Period Cash Flow | 23.1 M |
Clearpoint |
Clearpoint Neuro Relative Risk vs. Return Landscape
If you would invest 1,463 in Clearpoint Neuro on December 21, 2024 and sell it today you would lose (141.00) from holding Clearpoint Neuro or give up 9.64% of portfolio value over 90 days. Clearpoint Neuro is currently does not generate positive expected returns and assumes 5.0649% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Clearpoint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clearpoint Neuro Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearpoint Neuro's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clearpoint Neuro, and traders can use it to determine the average amount a Clearpoint Neuro's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0089
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLPT |
Estimated Market Risk
| 5.06 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clearpoint Neuro is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clearpoint Neuro by adding Clearpoint Neuro to a well-diversified portfolio.
Clearpoint Neuro Fundamentals Growth
Clearpoint Stock prices reflect investors' perceptions of the future prospects and financial health of Clearpoint Neuro, and Clearpoint Neuro fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearpoint Stock performance.
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.72) % | ||||
| Current Valuation | 353.18 M | ||||
| Shares Outstanding | 27.63 M | ||||
| Price To Earning | (3.36) X | ||||
| Price To Book | 14.56 X | ||||
| Price To Sales | 12.03 X | ||||
| Revenue | 31.39 M | ||||
| Gross Profit | 19.12 M | ||||
| EBITDA | (19.75 M) | ||||
| Net Income | (18.91 M) | ||||
| Cash And Equivalents | 45.14 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 3.57 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 10.33 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (8.95 M) | ||||
| Earnings Per Share | (0.70) X | ||||
| Market Capitalization | 377.73 M | ||||
| Total Asset | 39.19 M | ||||
| Retained Earnings | (191.37 M) | ||||
| Working Capital | 23.01 M | ||||
| Current Asset | 8.1 M | ||||
| Current Liabilities | 1.85 M | ||||
About Clearpoint Neuro Performance
Assessing Clearpoint Neuro's fundamental ratios provides investors with valuable insights into Clearpoint Neuro's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Clearpoint Neuro is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 204.19 | 394.35 | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.68) | (0.72) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (0.74) | (0.71) |
Things to note about Clearpoint Neuro performance evaluation
Checking the ongoing alerts about Clearpoint Neuro for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearpoint Neuro help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clearpoint Neuro generated a negative expected return over the last 90 days | |
| Clearpoint Neuro has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 31.39 M. Net Loss for the year was (18.91 M) with profit before overhead, payroll, taxes, and interest of 19.12 M. | |
| Clearpoint Neuro currently holds about 45.14 M in cash with (8.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Latest headline from finance.yahoo.com: Micro Medical Solutions Appoints Board of Directors |
- Analyzing Clearpoint Neuro's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearpoint Neuro's stock is overvalued or undervalued compared to its peers.
- Examining Clearpoint Neuro's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearpoint Neuro's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearpoint Neuro's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearpoint Neuro's stock. These opinions can provide insight into Clearpoint Neuro's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.